GSK already scores pretty well among the top 14 pharma companies when it comes to R&D efficiency – ranking third behind Pfizer and Novartis in an analysis of R&D productivity published last year ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents, the ...

WIRED is where tomorrow is realized. It is the essential source of information and ideas that make sense of a world in constant transformation. The WIRED conversation illuminates how technology is ...

C3.ai Inc. (AI) reported stronger-than-expected earnings for Q4 2025, with a narrower loss per share and revenue surpassing forecasts. The company’s stock surged by 10.17% in after-hours trading ...

GSK has posted a solid set of financial results in the first quarter of this year and said it is not too worried about the financial impact of potential pharma-specific US tariff rules. The UK ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts-based Affinivax, with another $1.2 billion in potential development milestones, to get its hands on the ASP3772 shot ...

The drugmaker's chief executive, Emma Walmsley noted this is the eighth time that GSK had headed the list, and comes after it pledged £1 billion ($1.2 billion) over the next decade to accelerate ...

GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...